Crescent Grove Advisors’s Gilead Sciences GILD Stock Holding History

Crescent Grove Advisors’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-5,836	Closed	-$484K	–	297
2023 Q1	$484K	Sell	5,836 -238	-4%	-$19.7K	0.06%	172
2022 Q4	$521K	Sell	6,074 -3,836	-39%	-$304K	0.05%	172
2022 Q3	$611K	Buy	+9,910	New	+$625K	0.07%	143
2022 Q1	–	Sell	-4,180	Closed	-$303K	–	299
2021 Q4	$303K	Buy	+4,180	New	+$288K	0.03%	232
2021 Q3	–	Sell	-4,237	Closed	-$292K	–	278
2021 Q2	$292K	Buy	+4,237	New	+$283K	0.03%	199
2018 Q1	–	Sell	-3,014	Closed	-$216K	–	150
2017 Q4	$216K	Hold	3,014	–	–	0.05%	126
2017 Q3	$244K	Buy	3,014 +14	+0.5%	+$1.07K	0.06%	117
2017 Q2	$212K	Buy	+3,000	New	+$200K	0.06%	130

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Crescent Grove Advisors's GILD Position: Q2 2023 in Review

Crescent Grove Advisors sold out of Gilead Sciences (GILD) in Q2 2023, closing a stake of 5,836 shares — an estimated $484K sold.

Crescent Grove Advisors first reported a position in GILD in Q2 2017 and held it in 8 quarters. The position peaked at $611K in Q3 2022. 1,701 funds tracked by Wall St. Rank hold GILD as of Q2 2023.

Crescent Grove Advisors reported no remaining Gilead Sciences position as of Q2 2023 after selling out during the quarter.
Crescent Grove Advisors sold 5,836 Gilead Sciences shares in Q2 2023, an estimated $484K.
Crescent Grove Advisors first reported a position in Gilead Sciences in Q2 2017 and held it in 8 quarters.
Crescent Grove Advisors's Gilead Sciences position peaked at $611K in Q3 2022.
1,701 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2023.

Based on Crescent Grove Advisors's 13F filing for Q2 2023, filed 13 Jul 2023.